Holen Sie sich die Stockscreener-App
73.43
1.28%
-0.95
Handel nachbörslich:
73.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$74.38
Offen:
$73.58
24-Stunden-Volumen:
5.45M
Relative Volume:
1.05
Marktkapitalisierung:
$28.26B
Einnahmen:
$4.66B
Nettoeinkommen (Verlust:
$836.30M
KGV:
35.08
EPS:
2.093
Netto-Cashflow:
$1.08B
1W Leistung:
+0.48%
1M Leistung:
-0.33%
6M Leistung:
-3.86%
1J Leistung:
-16.38%
1-Tages-Spanne:
$73.03
$74.35
1-Wochen-Bereich:
$70.81
$74.49
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
73.43 | 28.63B | 4.66B | 836.30M | 1.08B | 2.093 |
|
ABT
Abbott Laboratories
|
116.35 | 202.16B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
387.46 | 147.74B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.66 | 124.39B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
76.85 | 112.40B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
86.47 | 49.85B | 6.07B | 1.06B | 799.60M | 1.8527 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DNB Asset Management AS Acquires 803,086 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Purchased by Banco Santander S.A. - MarketBeat
DexCom (DXCM) Expands Board with New Appointment - GuruFocus
Dexcom Adds Google Executive Rick Osterloh to Board - TipRanks
Dexcom appoints Google executive Rick Osterloh to board - Investing.com
Dexcom Appoints Rick Osterloh to Board of Directors - The Joplin Globe
DexCom, Inc. Appoints Rick Osterloh to Board of Directors, Effective February 26, 2026 - marketscreener.com
Westfield Capital Management Co. LP Trims Stake in DexCom, Inc. $DXCM - MarketBeat
Aristotle Growth Equity Fund Bets on DexCom (DXCM) Due to Its Expanding CGM Market Leadership - Insider Monkey
Fox Run Management L.L.C. Purchases Shares of 18,368 DexCom, Inc. $DXCM - MarketBeat
HighTower Advisors LLC Lowers Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom Weighs GLP 1 CGM Tailwind Against Valuation And Momentum Signals - Yahoo Finance
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Morningstar
Assessing DexCom (DXCM) Valuation After Short Term Gains And A 14.5% Undervaluation Narrative - simplywall.st
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars - The Globe and Mail
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars - The Motley Fool
Dexcom announces upcoming conference presentation - marketscreener.com
Dexcom Announces Upcoming Conference Presentation - The Joplin Globe
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat - Finviz
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
I Tried Dexcom’s Stelo, a Glucose Biosensor, for 30 Days. Here’s What I Learned - Athletech News
I Tried Dexcom’s Stelo Glucose Biosensor for 30 Days. Here’s What I Learned - Athletech News
DexCom: How Product Innovation and Feature Adoption Are Expanding Its Diabetes Opportunity! - Smartkarma
Dexcom’s CEO to Chair AdvaMed’s Diabetes Sector - Medical Product Outsourcing
DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership - Insider Monkey
DexCom, Inc. (DXCM): Investor Outlook Highlights 16.94% Upside Potential and Strong Buy Ratings - DirectorsTalk Interviews
Did DexCom's (DXCM) Strong 2025 Results and Buybacks Just Reframe Its 2026 Growth Story? - Yahoo Finance
Public Sector Pension Investment Board Decreases Holdings in DexCom, Inc. $DXCM - MarketBeat
Is DexCom Inc. a strong growth stockJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
DexCom, Inc. $DXCM Shares Bought by Premier Fund Managers Ltd - MarketBeat
Jupiter Asset Management Ltd. Takes Position in DexCom, Inc. $DXCM - MarketBeat
Aurora Investment Counsel Makes New $2.29 Million Investment in DexCom, Inc. $DXCM - MarketBeat
DexCom G7 Rollout And Expansion Shape Growth And Competitive Outlook - Sahm
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
King Luther Capital Management Corp Reduces Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
SENS Eversense 365 Integrated With twiist Gains Full Availability - TradingView
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 25,094 Shares of DexCom, Inc. $DXCM - MarketBeat
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call - The Globe and Mail
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business - simplywall.st
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call - Finviz
Vanguard Group Inc. Purchases 1,133,638 Shares of DexCom, Inc. $DXCM - MarketBeat
P/E Ratio Insights for DexCom - Benzinga
NEOS Investment Management LLC Boosts Position in DexCom, Inc. $DXCM - Defense World
DexCom, Inc. $DXCM Shares Sold by Shell Asset Management Co. - MarketBeat
What Wall Street predicts for DexCom Inc. stock pricePortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Dexcom G6 Glucose Monitor Lawsuit Claims Manufacturer’s Device Modifications Resulted in Teen’s Death - AboutLawsuits.com
Dexcom Stock After Volatility: Is This High-Growth Medtech Now Mispriced? - AD HOC NEWS
Aberdeen Group plc Increases Position in DexCom, Inc. $DXCM - MarketBeat
What DexCom (DXCM)'s Margin Beat And Reaffirmed 2026 Outlook Means For Shareholders - simplywall.st
The DexCom, Inc. (NASDAQ:DXCM) Yearly Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook - Bitget
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):